


Narayana Hrudayalaya


7 January 2025


About company


Narayana Hrudayalaya Ltd, now known as Narayana Health, is a leading multispecialty healthcare provider in India, headquartered in Bengaluru. Established by Dr. Devi Prasad Shetty in 2000, it operates a network of hospitals offering affordable, high-quality medical care, especially in cardiac and critical care. The organization is renowned for its patient-centric approach and innovative healthcare delivery models. With a strong presence across India and abroad, Narayana Health aims to make advanced medical care accessible to all.

Financials










MARKET CAP	₹ 27,647 Cr.
P/E RATIO	35.5
DIVIDEND YIELD	0.29%
ROCE	26.5%
ROE	31.4%
FACE VALUE	10.00
3 YEARS SALES GROWTH	25%
3 YEARS PROFIT GROWTH	365%



Our recommendation

MOMENTUM SWING: BUY NH BETWEEN 1345-1350 TARGET 1420/1500 STOPLOSS BELOW 1280

Technical analysis

Narayana Hrudayalaya Ltd Share prices are trading positive since yesterday as it broke out from consolidation phase. Volumes are increasing along with the upward movement in the stock, which indicate some strength in this rally. The breakout comes after a short-term period of consolidation, which can be seen in image below marked under a rectangle draw. The bullish view is backed by couple of indicators, such as the prices are trading above its 20 EMA level; the volumes are increasing along with the prices which can indicate strength in this bullish move. Thus, we recommend buying NH share.





Disclaimer

I, Ruchi Nahar, SEBI Registered Research Analyst (INH000014544) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified CA, CS and MBA, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverage my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

7 January 2025